This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
5 Low-Cost Top-Ranked ETFs to Tap at Discounted Prices
by Sanghamitra Saha
Grab these ETFs that have a solid Zacks Rank and are available at extremely low prices. These funds have a low expense ratio too.
Technology & Biotech: 2 ETFs to Watch on Outsized Volume
by Sanghamitra Saha
XLK and XBI saw massive trading volumes in yesterday trading.
4 Sector ETF Winners of Bull Market Look Resilient to Virus
by Sanghamitra Saha
These sector ETFs emerged winners in the 11-year old bull market and may survive despite the coronavirus scare.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
ETFs to Play as Goldman Lowers US Q1 GDP Outlook
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can tap as aggravating coronavirus outbreak lead to a cut in U.S. GDP growth forecast.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
3 Key Investment Themes: Zacks FEB Market Strategy
by John Blank
Where institutional money flows are where stock returns rise. This month, after I followed the money, I focused on visible long-term investing themes. Here are three worth knowing about...
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
5 ETFs to Protect Your Portfolio From Coronavirus Threat
by Sweta Killa
We have highlighted five ETFs that could benefit investors' portfolio and could provide some shelter from the crisis.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Top Performing ETFs of the Decade
by Neena Mishra
We take a look at the best performing areas of the decade
Top-Ranked ETFs, Stocks From Top Sector of the Last Decade
by Sweta Killa
Amid a plethora of challenges, Wall Street was on a spectacular run over the last decade, rising from the depths of the financial crisis and Great Recession.
10 Top-Performing ETFs of the Past Decade
by Sanghamitra Saha
These ETFs have emerged out as one of the top performers in the past decade.
Top ETF Areas for 2020
by Sweta Jaiswal, FRM
As ETF investing constantly climbs the popularity charts, we highlight a few good ETF areas that investors can bank on for 2020.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Decorating a Christmas Tree of Top-Ranked ETFs
by Sweta Killa
We have built a tree with the top-ranked ETFs that have the potential to outperform in 2020.
Santa Rally Sets In: Bet on 5 Top High-Beta ETFs With Value
by Sanghamitra Saha
As Wall Street bulls rage on, investors can play high-beta ETFs to make the most of the Santa rally. These ETFs offer solid value and allay overpricing concerns.
Will Biotech ETFs Excel in Election Year Post a Surge in 2019?
by Sanghamitra Saha
Can biotech ETFs repeat its success story of 2019 in the election year of 2020?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE